In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Structured follow-up program of patients with heart failure: impact on quality of life and prognosis.

Session Patient management - From oral treatment to transplant

Speaker Joao AGOSTINHO

Congress : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Multidisciplinary Interventions
  • Session type : Rapid Fire Abstracts
  • FP Number : 1536

Authors : JPR Agostinho (Lisbon,PT), J Rigueira (Lisbon,PT), A Nunes-Ferreira (Lisbon,PT), R Santos (Lisbon,PT), I Aguiar-Ricardo (Lisbon,PT), I Goncalves (Lisbon,PT), T Guimaraes (Lisbon,PT), R Pires (Coimbra,PT), F Veiga (Lisbon,PT), M Mendes Pedro (Lisbon,PT), FJ Pinto (Lisbon,PT), D Brito (Lisbon,PT)


JPR Agostinho1 , J Rigueira1 , A Nunes-Ferreira1 , R Santos1 , I Aguiar-Ricardo1 , I Goncalves1 , T Guimaraes1 , R Pires2 , F Veiga1 , M Mendes Pedro1 , FJ Pinto1 , D Brito1 , 1Cardiology Department, Santa Maria Hospital, CHLN, CCUL, Lisbon University - Lisbon - Portugal , 2Faculty of Psychology, CINEICC, University of Coimbra - Coimbra - Portugal ,

On behalf: RICA-HFTeam


Introduction: Patients with heart failure (HF) benefit from regular clinical follow-up in order to maintain therapeutic optimization and to identify early signs of decompensation, thereby reducing readmission rates and improving prognosis. However, the magnitude of this potential benefit is seldom objectified.

Objective: To evaluate the actual impact of the implementation of a structured follow-up program in pts with HF, regarding quality of life (QoL) and hospitalization and mortality rates.

Methods: Nested-case control study, with prospective data registry of 50 consecutive pts discharged after hospitalization for acute HF (AHF). This population (study group) was followed (HF team) at 10 days, 3, 6 and 12 months after discharge, with predefined procedures (by protocol), including clinical evaluation, therapeutic optimization (according to ESC guidelines), laboratorial, electrocardiographic and echocardiographic evaluations, and QoL assessment [Kansas City Cardiomyopathy Questionnaire (KCCQ)]. The control group consisted of 100 pts hospitalized for AHF and regularly followed after discharged but prior to the implementation of the protocol. Cox Regression, Kaplan-Meier survival analysis and Wilcoxon test were the statistical methods used.

Results: The study group (mean age: 67.1±11 years, 75.5% males) had a mean left ventricular ejection fraction (LVEF) of 27.6±10.3% (85.7% with LVEF<40%) at discharge. Sixteen pts (31%) were discharged in NYHA I functional class, 63.3% in class II and 6.1% in class III. Demographics and all functional cardiac variables were similar in the two. Mean follow-up time was 8.2±5.3 months in the study group, and 8±4.7 months in the control group (p=NS).

In the study group, there was a significant improvement in LVEF (p<0.001), NYHA functional class (p=0.001), and in all the parameters assessed by the KCCQ, namely in symptoms (p<0.001) and overall QoL (p<0.001). There was also an effective optimization of treatment during follow up, including the up-titration of recommended drugs: compared to the doses of pharmacological therapies previously used before the index-admission for AHF, a significant increase in doses of angiotensin converting enzyme inhibitor/angiotensin II receptor antagonists (p<0.001), beta-blockers (p<0.001) and mineralocorticoids receptor antagonists (p<0.001), was achieved during follow up.

In comparison with the results observed in the control group, the group included in the structured follow-up program showed a significant reduction in all cause readmissions (24.5% vs 61.2%, p=0.001), HF readmissions (16.3% vs 36.7%, p=0.001) and total mortality (2% vs 18.4%, p=0.001) during follow up. Conclusion: A structured follow-up program of HF patients allowed a significant reduction in readmission and mortality rates in the medium term, and was associated with a significant improvement in functional class, quality of life, and LVEF. These results support the imperative need to establish such programs.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are